Dicot Pharma

Longevity, or healthy aging, can be described as living a long life in good health. Research and innovation in the longevity field are considered among the most exciting and fast-growing areas for life science investments. Oppenheimer recently released a report pointing to the life-extending benefits of treating ED and its potential role as a marker for underlying diseases. The report also highlights the shortcomings of current ED treatments and emphasizes the need for new modalities. Dicot Pharma’s candidate LIB-01 is singled out as particularly promising due to its long duration of action and competitive safety profile observed to date in clinical development, as well as its differentiated mechanism of action. Unlike current ED treatments on the market, LIB-01 is not a PDE5-inhibitor, and has the potential to be first-in-class in ED treatment.

Dicot Pharma has been invited to Oppenheimer’s company showcase, where life science companies representing the next wave of innovation in the field will present their work.

“The fact that erectile dysfunction is recognized as a key factor within longevity, and that our ED drug candidate LIB-01 is being specifically highlighted, is a significant confirmation of the relevance of our work. We look forward to sharing further insights during today’s event,” says Elin Trampe, CEO of Dicot Pharma.